UNC Health Medication Formulary
Add Formweb to your mobile device
System Formulary Update
Ocrelizumab and hyaluronidase (Ocrevus Zunovo)
April 29, 2025
Situation: Ocrelizumab and hyaluronidase (Ocrevus Zunovo) subcutaneous injection was approved for addition to the UNC Health System Formulary at the System Pharmacy and Therapeutics Committee meeting.
Background: The following medication was reviewed: Ocrelizumab and hyaluronidase subcutaneous injection
Assessment/Recommendation: System P&T voted to include the following product to the UNC Health Medication Formulary
- Ocrelizumab 920 mg and hyaluronidase 23,000-unit subcutaneous injection
Formulary/Epic Changes will Go-Live on Tuesday, May 27th